Cannabis Science Inc. (OTCMKTS:CBIS) has announced that Cannabis Science Europe GmbH, its wholly-owned
subsidiary, has managed to successful complete the testing as well as
validations of its short-time vacuum distillation process. The distillation is
for enhancement of CBD extracts containing high Cannabidiolic Acid levels that
is subsequently converted into CBD powder and water purified soluble CBDA.
Cannabis Science’s proprietary distillation process
In the process
of completing the testing the company has managed to quickly and affordably
expand its present production capacity to more than 1,000 kilograms of CBD
extract and purified CBDA per month. Cannabis Science is expecting to expand its
production ability so as to meet its clinical, wholesale and private label
short-time vacuum distillation process that the company is using determines the
appropriate temperature, pressure and the accurate time to minimise loss of
CBDA as well as the other essential cannabinoid acids. In the testing of the
process the company used CBD extract that contained less than 0.2% THC levels
and 7.3% CBD and in the first step of purification cannabis Science managed to
produce Purified extract containing 0.6% THC and 26% CBD. From the purified
extract the company managed to produce CBD powder that contains 3.5% CBD, 3.5%
CBDA and THC levels below 0.02%.
Bypassing oxidation process produces quality CBDA and
will become unstable during the oxidation process when mixed with water but
with the proprietary distillation process the company will manage to bypass the
oxidation process. As a result they will provide an effective product that
keeps the nutritional CBD and CBDA levels for over a long time compared to the
water-diluted CBD products.
Co-founder of Cannabis Science Raymond Dabney stated that the company is
preparing itself for its Global Development Initiatives. He added the
distillation process is another significant milestone for the company as it
aggressively reaches into the global market with cost effective purified water
soluble CBDA powders ad CBD extracts. Dabney said that the company plans to
increase its supplies for clinical research develop the company as well as
produce private label products for clients.